Morgan Stanley
KLRS

Morgan Stanley’s Kalaris Therapeutics KLRS Stock Holding History

Morgan Stanley’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$221K Buy
38,344
+10,396
+37% +$92.3K ﹤0.01% 5828
2025
Q4 		$236K Buy
27,948
+3,030
+12% +$19.4K ﹤0.01% 5867
2025
Q3 		$144K Buy
24,918
+22,954
+1,169% +$75.9K ﹤0.01% 6012
2025
Q2 		$5.24K Buy
1,964
+668
+52% +$3.02K ﹤0.01% 7021
2025
Q1 		$10.4K Buy
1,296
+299
+30% +$2.93K ﹤0.01% 6786
2024
Q4 		$9.63K Sell
997
-1,063
-52% -$16.1K ﹤0.01% 6819
2024
Q3 		$38.3K Sell
2,060
-981
-32% -$17.2K ﹤0.01% 6287
2024
Q2 		$50.6K Sell
3,041
-12,338
-80% -$218K ﹤0.01% 6163
2024
Q1 		$267K Sell
15,379
-29,188
-65% -$476K ﹤0.01% 5610
2023
Q4 		$697K Buy
44,567
+20,494
+85% +$808K ﹤0.01% 5473
2023
Q3 		$1.19M Buy
24,073
+12,228
+103% +$833K ﹤0.01% 4695
2023
Q2 		$926K Buy
11,845
+3,722
+46% +$354K ﹤0.01% 4877
2023
Q1 		$736K Sell
8,123
-1,687
-17% -$215K ﹤0.01% 5041
2022
Q4 		$1.16M Sell
9,810
-7,692
-44% -$1.3M ﹤0.01% 4788
2022
Q3 		$3.17M Buy
17,502
+11,362
+185% +$1.77M ﹤0.01% 4060
2022
Q2 		$551K Buy
6,140
+2,137
+53% +$224K ﹤0.01% 5366
2022
Q1 		$622K Buy
4,003
+1,884
+89% +$376K ﹤0.01% 5279
2021
Q4 		$632K Sell
2,119
-239
-10% -$111K ﹤0.01% 5404
2021
Q3 		$1.36M Buy
2,358
+343
+17% +$159K ﹤0.01% 4852
2021
Q2 		$914K Sell
2,015
-1,160
-37% -$599K ﹤0.01% 5133
2021
Q1 		$1.71M Buy
3,175
+1,250
+65% +$1.05M ﹤0.01% 4377
2020
Q4 		$1.7M Buy
1,925
+1,735
+913% +$1.33M ﹤0.01% 4285
2020
Q3 		$120K Buy
+190
New +$130K ﹤0.01% 5346

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley's KLRS Position: Q1 2026 in Review

Morgan Stanley increased its Kalaris Therapeutics (KLRS) stake by 37% in Q1 2026, buying an estimated $92.3K and bringing the position to 38,344 shares worth $221K. The position accounts for ﹤0.01% of the portfolio, ranked #5828.

Morgan Stanley first reported a position in KLRS in Q3 2020 and has held it in 23 quarters since. The position peaked at $3.17M in Q3 2022. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Morgan Stanley held 38,344 shares of Kalaris Therapeutics worth $221K as of Q1 2026.
  • Morgan Stanley bought 10,396 Kalaris Therapeutics shares in Q1 2026, an estimated $92.3K.
  • Kalaris Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5828 holding.
  • Morgan Stanley first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Morgan Stanley's Kalaris Therapeutics position peaked at $3.17M in Q3 2022.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.